Long-term Study of SYR-472

Phase 3CompletedNCT01431807

Takeda680 enrolled

Overview

To evaluate the safety and efficacy of long-term treatment with SYR-472 in diabetic patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

680

Conditions

Diabetes Mellitus

Interventions

SYR-472DRUG

oral, for up to 52 weeks.

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The participant is an outpatient. 2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 3. Diabetes Mellitus Exclusion Criteria: 1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease. 2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Locations (41)

Unnamed facility

Akita, Akita, Japan

Outcomes

Primary Outcomes

Adverse events

Time frame: 52 weeks.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.